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Immune therapy of cancer has recently experienced a great breakthrough with prolonged overall 
survival in patients with metastatic disease following the use of checkpoint inhibitors and T cell 
therapy with ex vivo expanded CD8+ cytotoxic T cells (CTLs). In the further development of 
immune therapies against cancer, vaccine formulations tailored to mount in vivo CTL responses 
towards co-delivered cancer antigens will be an important hallmark. Recognition of antigen-derived 
peptides presented in the context of major histocompatibility complex (MHC) class I molecules on 
cancer cells is a requirement for activation of CTLs. Previously, the development of therapeutic 
anti-cancer vaccines have largely been based on rodent models, in particular mice; however the 
majority of these fail to establish a therapeutic response once put into clinical trials. Pigs have the 
potential of serving as a model superior to rodents as they are more closely related to humans in 
terms of immunology and physiology. Here, we introduce pigs as a supplementary large animal 
model for human cancer vaccine development via the use of our unique technology for swine 
leukocyte antigen (SLA) production. IDO and RhoC, two tumor antigens previously identified as 
important players in human cancer development and progression, were used as vaccine targets. 
Using peptide-MHC-I binding predictors we identified IDO-derived and RhoC-derived candidate 
peptides potentially binding to five different broadly distributed SLA molecules. We measured the 
peptide-SLA complex stability of these and found a total of 89 stable (t½ ≥ 0.5 hours) peptide-MHC 
complexes with SLA-1*04:01, -1*07:02, -2*04:01, -2*05:02 and/or -3*04:01. For a pilot study, 12 
pigs were immunized with overlapping 20-mer peptides spanning the entire IDO and RhoC 
sequences formulated in a panel of CTL-inducing adjuvants. Vaccine and adjuvant efficacy will be 
evaluated through immunological assays among others including ex vivo stimulation of whole blood 
with identified stable SLA-binding peptides and quantification of peptide-specific CTLs. Hence, 
these data elucidate the potential in using pigs as a large animal model for human anti-cancer 
vaccine development. 
